Validation experiment designed to validate causal mechanisms targeting NTN1 in Primary mouse model. Primary outcome: Proportion of EMT tumor cells, metastasis number, chemotherapy sensitivity
This experiment investigated the therapeutic effects of NP137, a netrin-1-blocking monoclonal antibody, on epithelial-to-mesenchymal transition and metastasis in the mouse skin SCC model. The study administered NP137 to mice with SCC and evaluated multiple outcomes including the proportion of EMT tumor cells, metastasis formation, and chemotherapy sensitivity. Results showed that NP137 treatment decreased EMT tumor cell proportions, reduced metastases, and increased sensitivity to chemotherapy, demonstrating the therapeutic potential of targeting netrin-1 in cancer treatment.
Administration of NP137 monoclonal antibody to mice with skin SCC, followed by assessment of EMT markers, metastasis counting, and chemotherapy response
Decreased EMT, reduced metastases, increased chemotherapy sensitivity
Significant reduction in EMT tumor cells and metastases with improved treatment response
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.